BioCardia Jumps After FDA Feedback Seen Positive for CardiAMP Approval
BioCardia Inc. shares surged over 50% in busy trading Friday. The move followed an announcement that the company received FDA meeting minutes that could allow its ongoing CardiAMP HF II trial to back a marketing application for its heart-failure cell therapy.